Clobetasol
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Clobetasol
- Molecular weight
- 410.91
- Structure (SMILES)
- C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl
- BETAMETHASONE IMPURITY B [EP IMPURITY]
- betamethasone impurity b ep impurity
- clobecort amex
- CLOBECORT AMEX
- clobetasol
- Clobetasol
- clobetasol [INN]
- CLOBETASOL [MI]
- CLOBETASOL [VANDF]
- Clobetasol [WHO-DD]
- clobetasol inn
- clobetasol mi
- CLOBETASOL PROPIONATE IMPURITY G [EP IMPURITY]
- clobetasol propionate impurity g ep impurity
- clobetasol vandf
- clobetasol who dd
- dovate
- DOVATE
- CAS registry numbers
- 25122-41-2
- ChEMBL ID
- CHEMBL1201362
- InChIKey
- FCSHDIVRCWTZOX-DVTGEIKXSA-N
- PubChem compound IDs
- 5311051
- FDA ingredient codes (UNII)
- ADN79D536H
- D07AD01
- S01BA17
Sources for recorded values
- 2590
- 21245
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- clobetasol propionate
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Median affinity
- 9.18
- Affinity units
- pKi
- Primary target
- Yes
- Condition
- Psoriasis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Stevens-Johnson Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004775
- Subject identifier
- D013262
- Condition
- Pemphigoid, Bullous
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007187
- Subject identifier
- D010391
- Condition
- Lichen Planus, Oral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008517
- Subject identifier
- D017676
- Condition
- Vulvar Lichen Sclerosus
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000623
- Subject identifier
- D007724
- Condition
- Lichen Sclerosus et Atrophicus
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000724
- Subject identifier
- D018459
- Condition
- Phlebitis
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001395
- Subject identifier
- D010689
- Condition
- Scleroderma, Localized
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001993
- Subject identifier
- D012594
- Condition
- Graft vs Host Disease
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0013730
- Subject identifier
- D006086
- Condition
- Bronchiolitis Obliterans Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0020547
- Subject identifier
- D000092122
- Condition
- Herpes Labialis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0043653
- Subject identifier
- D006560
- Condition identifier
- EFO_0000676
- Condition identifier
- EFO_0004775
- Condition identifier
- EFO_0007187
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008517
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000623
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000724
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000760
- Condition identifier
- EFO_1001395
- Condition identifier
- EFO_1001993
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006491
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006570
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006585
- Condition identifier
- MONDO_0006604
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0013730
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019082
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019810
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0020547
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0026045
- Condition identifier
- MONDO_0043653
- Highest recorded phase
- 2
- Event
- acarodermatitis
- Reports
- 9
- Reporting signal score
- 35.4015
- Event
- acinetobacter infection
- Reports
- 7
- Reporting signal score
- 26.8485
- Event
- acute graft versus host disease in skin
- Reports
- 5
- Reporting signal score
- 12.4309
- Event
- adrenal atrophy
- Reports
- 2
- Reporting signal score
- 11.6202
- Event
- adrenal insufficiency
- Reports
- 36
- Reporting signal score
- 106.195
- Event
- adrenal suppression
- Reports
- 12
- Reporting signal score
- 50.4693
- Event
- alopecia scarring
- Reports
- 7
- Reporting signal score
- 37.2915
- Event
- alopecia universalis
- Reports
- 4
- Reporting signal score
- 17.0452
- Event
- application site atrophy
- Reports
- 3
- Reporting signal score
- 20.1031
- Event
- atrophy
- Reports
- 5
- Reporting signal score
- 14.4005
- Event
- beta haemolytic streptococcal infection
- Reports
- 7
- Reporting signal score
- 24.7341
- Event
- blood corticotrophin decreased
- Reports
- 5
- Reporting signal score
- 20.5257
- Event
- blood cortisol decreased
- Reports
- 8
- Reporting signal score
- 31.6062
- Event
- bone infarction
- Reports
- 4
- Reporting signal score
- 14.6292
- Event
- bronchiolitis obliterans syndrome
- Reports
- 6
- Reporting signal score
- 35.697
- Event
- central obesity
- Reports
- 6
- Reporting signal score
- 23.371
- Event
- chorioretinopathy
- Reports
- 18
- Reporting signal score
- 67.3047
- Event
- chronic graft versus host disease in skin
- Reports
- 5
- Reporting signal score
- 16.8625
- Event
- condition aggravated
- Reports
- 56
- Reporting signal score
- 37.4442
- Event
- cushing's syndrome
- Reports
- 87
- Reporting signal score
- 403.507
- Event
- cushingoid
- Reports
- 28
- Reporting signal score
- 106.184
- Event
- cytomegalovirus infection reactivation
- Reports
- 6
- Reporting signal score
- 16.0649
- Event
- delayed myelination
- Reports
- 6
- Reporting signal score
- 43.6676
- Event
- dermal absorption increased
- Reports
- 2
- Reporting signal score
- 13.1654
- Event
- dermatitis atopic
- Reports
- 7
- Reporting signal score
- 16.033
And 57 more, listed on the interactive page.
- NCT00297011
- NCT00393263
- NCT05010421
- NCT00715975
- NCT03399526
- NCT00757874
- NCT03961126
- NCT01557517
- NCT01699412
- NCT02319616
- NCT02680717
- NCT02744378
- NCT04364555
- NCT03286582
- NCT04685031
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 2
- Polar surface area
- 74.6
- Calculated partition coefficient (ALogP)
- 3.14
- Calculated partition coefficient (XLogP)
- 2.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 28
- Molecular formula
- C22H28ClFO4
- Monoisotopic mass
- 410.1660152
- Natural product
- No
- Recorded assays
- 158
- Active assays
- 23
- Confirmatory
- Summary
- Anti-Inflammatory Agents
- Glucocorticoids
Related records
Trials (27)
- 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat
- A Comparison of Photodynamic Therapy and Topical Clobetasol in Treatment of Oral Lichen Planus: a Split-Mouth Randomised Controlled Study
- A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
- Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis
- Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease
- Clobetasol for Oral Graft-Versus-Host Disease
- Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus
- Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea
- Comparison Between Corticosteroid and Topical Steroids in the DRESS
- Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound
- Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus
- Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
- Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis
- Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- Impact of Topical Clobetasol on Gingival Crevicular Fluid miRNAs in Subjects Affected by Oral Lichen Planus
- Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy
- Laser vs Clobetasol for Lichen Sclerosus
- Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
- Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus
In development for (11)
- Bullous pemphigoid Phase 2
- Chronic graft versus host disease Phase 2
- Graft versus host disease Phase 3
- Herpes labialis Phase 2
- Lichen disease Phase 3
- Lichen planus, oral Phase 2
- Phlebitis Phase 1
- Psoriasis Phase 2
- Scleroderma Phase 1
- Toxic epidermal necrolysis Phase 1
- Vulvar lichen sclerosus Phase 2
Other linked conditions (1)
- Rosacea